1800-272-662
Shopping Cart 0
countryflagAU
Login

Cambium Bio Ltd

Healthcare AU CMB

0.48AUD
-(-%)

Last update at 2026-03-13T00:52:00Z

Day Range

0.480.48
LowHigh

52 Week Range

0.190.60
LowHigh

Fundamentals

  • Previous Close 0.48
  • Market Cap11.02M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-0.72459M
  • Revenue TTM0.99M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 1.02M
  • Diluted EPS TTM-0.14

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -3.94908M -2.25576M -2.67308M -4.30973M 1.91M
Minority interest - - - - -
Net income -3.84425M -2.25576M -1.68688M -4.38239M 2.15M
Selling general administrative 1.57M 1.17M 1.08M 2.78M 4.23M
Selling and marketing expenses - - 0.70M - -0.25366M
Gross profit 0.46M 0.00072M -0.00642M -0.02496M 7.96M
Reconciled depreciation 0.00496M 0.00071M 0.00528M 0.02M 0.05M
Ebit -3.80927M -1.98457M -2.24911M -4.24480M 1.64M
Ebitda -3.80431M -1.98386M -2.24269M -4.21984M 1.69M
Depreciation and amortization 0.00496M 0.00071M 0.00642M 0.02M 0.05M
Non operating income net other - - - - -
Operating income -4.29563M -1.83440M -2.24911M -4.24480M 1.64M
Other operating expenses 4.97M 1.84M 2.25M 4.65M 5.43M
Interest expense 0.03M 0.27M 0.35M 0.07M 0.40M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.03M 0.00001M 0.26M 0.00000M 0.28M
Net interest income -0.00234M -0.27119M -0.29020M -0.07265M -0.07504M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.10483M - -0.98619M 0.07M -0.85128M
Total revenue 0.67M 0.00072M 0.00000M 0.00000M 7.07M
Total operating expenses 4.76M 1.84M 2.24M 4.65M 5.38M
Cost of revenue 0.21M 0.05M 0.00642M 0.02M -0.88880M
Total other income expense net 0.35M -0.42137M -0.42397M -0.06493M 0.27M
Discontinued operations - - - - -
Net income from continuing ops -3.84425M -2.25576M -3.37688M -4.30973M 2.15M
Net income applicable to common shares - - -1.68688M -4.30973M 2.76M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 3.30M 5.65M 0.71M 2.55M 8.51M
Intangible assets 2.45M 2.45M - - 0.00000M
Earning assets - - - - -
Other current assets - - 0.03M 0.03M 0.02M
Total liab 1.46M 2.87M 2.53M 1.48M 4.36M
Total stockholder equity 1.84M 2.78M -1.81496M 1.07M 4.15M
Deferred long term liab - - - - -
Other current liab - - 0.08M 0.31M 0.42M
Common stock - - 38.62M 38.62M 38.26M
Capital stock 46.54M 43.63M 38.62M 38.62M 38.29M
Retained earnings -46.59109M -42.74684M -42.27701M -38.95131M -34.64879M
Other liab - - - 0.00092M 3.06M
Good will - - - - -
Other assets - - - 1.75M -
Cash 0.17M 2.86M 0.30M 0.10M 3.79M
Cash and equivalents - - - - -
Total current liabilities 1.29M 2.40M 2.53M 1.48M 1.30M
Current deferred revenue - - - - -
Net debt 0.32M - 1.64M 0.91M -3.77885M
Short term debt - - 1.95M 1.01M 0.00530M
Short long term debt 0.32M - 1.95M 1.00M -
Short long term debt total - - 1.95M 1.01M 0.01M
Other stockholder equity - - 1.84M 1.41M -0.00000M
Property plant equipment - - 0.00071M 0.02M 0.03M
Total current assets 0.47M 3.20M 0.71M 0.79M 6.73M
Long term investments 0.38M - - 1.75M -
Net tangible assets - - -0.12496M 1.07M 4.15M
Short term investments - - 0.00000M 0.07M 0.57M
Net receivables 0.26M 0.26M 0.38M 0.56M 2.91M
Long term debt 0.17M 0.47M - - 1.53M
Inventory - - 0.00000M 0.04M -
Accounts payable 0.60M 1.22M 0.50M 0.16M 0.87M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 1.84M 1.41M 0.54M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.00109M 0.00000M - - -1.75000M
Deferred long term asset charges - - - - -
Non current assets total 2.83M 2.45M 0.00071M 1.77M 1.78M
Capital lease obligations - - - 0.00837M 0.01M
Long term debt total - - 0.00000M 0.00251M 0.00855M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -0.33348M -0.41613M -0.04894M -0.00847M -0.00778M
Change to liabilities - - -0.00837M -0.70527M -1.35655M
Total cashflows from investing activities -0.33348M -0.41613M -0.04894M -0.00847M -0.00778M
Net borrowings - -0.34702M 0.95M 1.19M -1.10000M
Total cash from financing activities 2.88M 3.13M 0.92M -0.09784M 0.40M
Change to operating activities - - 0.27M 0.22M -0.31456M
Net income -3.84425M -2.25576M -1.68688M -4.38239M 2.76M
Change in cash -2.69854M 2.56M 0.21M -3.69757M 2.81M
Begin period cash flow 2.86M 0.30M 0.10M 3.79M 0.98M
End period cash flow 0.17M 2.86M 0.30M 0.10M 3.79M
Total cash from operating activities -5.24202M -0.15586M -0.66046M -4.35743M 2.42M
Issuance of capital stock 2.88M 3.48M - - 1.50M
Depreciation 0.00496M 0.00071M 0.00642M 0.02M 0.05M
Other cashflows from investing activities -0.32823M -0.41613M -0.04894M - 0.00000M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables -0.00190M 0.31M 0.11M -0.10230M 1.47M
Sale purchase of stock - - -0.03075M - 0.00000M
Other cashflows from financing activities - - 1.35M 1.16M 1.50M
Change to netincome - - 0.64M 1.29M -0.18983M
Capital expenditures 0.00526M 0.00000M 0.00000M 0.00847M 0.00778M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -1.04822M 1.96M 0.38M -0.59178M -0.20471M
Stock based compensation - - - - -
Other non cash items -0.35450M 0.14M 0.64M 0.59M -0.18983M
Free cash flow -5.24727M -0.15586M -0.66046M -4.36589M 2.41M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
CMB
Cambium Bio Ltd		 - -% 0.48 - 10.58 2030.42 4.26 4.79 79.66
CSL
CSL Ltd		 -0.37 0.26% 140.66 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 -0.31 2.75% 10.98 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.06 2.84% 2.05 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.62% 11.57 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Cambium Bio Limited, a clinical-stage regenerative medicine company, focuses on developing biologics for ophthalmology and tissue repair applications. The company provides lead product candidate is Elate Ocular for the treatment of dry eye disease. The company also develops Progenza, a stem cell platform for knee osteoarthritis and other tissue repair indications; and Sygenus, for wound healing indications. Cambium Bio Limited is headquartered in Bella Vista, Australia.

Cambium Bio Ltd

Unit 2.06/31 Lexington Dr, Bella Vista, NSW, Australia, 2153

Key Executives

Name Title Year Born
Mr. Karolis Rosickas Chief Executive Officer NA
Prof. Graham Vesey Ph.D. Chief Scientific Officer & Executive Director 1965
Dr. Charlotte Morgan Ph.D. Head of Research & Development NA
Ling Leung Hang Company Secretary NA
Mr. Karolis Rosickas M.B.A., M.S. Chief Executive Officer NA
Dr. Edmund Kemp Waller FACP, M.D., Ph.D. Chief Scientific Officer & Executive Director NA
Mr. Terence Allen Walts Executive Director 1948
Hang Ling Leung Company Secretary NA
Dr. Edmund Kemp Waller FACP, M.D., Ph.D. Chairman & Chief Scientific Officer NA
Mr. Mark Andrew Licciardo B Bus (Acc), FCIS, FGIA, GAICD, GradDip CSP Company Secretary 1964

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.